Research from University of Rome "Tor Vergata" Reveals New Findings on Rheumatoid Arthritis (The rs11568820 Variant in the Promoter Region of Vitamin D Receptor Gene Is Associated with Clinical Remission in Rheumatoid Arthritis Patients...).

A recent study conducted by researchers at the University of Rome "Tor Vergata" has found a potential association between a genetic variant in the vitamin D receptor (VDR) gene and the response to therapy in rheumatoid arthritis (RA) patients. The study, which included 178 Italian patients with RA, examined the rs11568820 variant in the promoter region of the VDR gene and its relationship to remission rates in patients receiving anti-TNF drugs. The findings suggest that the variant T allele of rs11568820 may be associated with a reduced remission rate in RA patients receiving anti-TNFa drugs. Further research is needed to fully understand the role of VDR genetic variability in the response to therapy and achieving remission in RA patients. [Extracted from the article]

Copyright of Genomics & Genetics Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)